HP
MRNA icon

HealthInvest Partners’s Moderna MRNA Stock Holding History

HealthInvest Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$33.6K Buy
+187
New +$30.6K 0.06% 25

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HealthInvest Partners's MRNA Position: Q4 2022 in Review

HealthInvest Partners opened a new position in Moderna (MRNA) in Q4 2022: 187 shares worth $33.6K. The stake represents 0.06% of the portfolio and ranks #25 among its holdings.

1,072 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • HealthInvest Partners held 187 shares of Moderna worth $33.6K as of Q4 2022.
  • Moderna was a new HealthInvest Partners position in Q4 2022.
  • Moderna made up 0.06% of HealthInvest Partners's portfolio in Q4 2022, its #25 holding.
  • 1,072 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.